And again, the historic FDA stance on not even this new administration. This new administration has made it clear their plan is to open up the regulatory pathways on peptides and stem cells and cash pay products and to figure out a pathway that makes sense for the American people while still honoring the safety and integrity of what they're trying to implement on a grander scale.